How to Buy rpglife Shares on Fincept?
You can buy RPG Life Sciences Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: RPG Life Sciences Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Rpglife, including updates on board meetings and corporate actions.
RPG Life Sciences Limited - https://www.rpglifesciences.com
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, and anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology, cardiovascular, pediatrics, neurology, anti-dengue, and dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
RPG Life Sciences Limited Share Price Today
2,431.00
OPEN
2,500.00
HIGH
2,370.05
LOW
2,407.95
CLOSE
38 K
VOLUME
3,603 Cr
Market Cap
30539
Average Volume
Healthcare
Sector
NSI
Exchange
RPG Life Sciences Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: RPGLIFE Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
RPG Life Sciences Limited |
RPGLIFE |
INE105J01010 |
Dividend - Rs 16 Per Share |
28 Jun 2024 |
8 |
N/A |
RPG Life Sciences Limited |
RPGLIFE |
INE105J01010 |
Dividend - Rs 12 Per Share |
21 Jul 2023 |
8 |
N/A |
RPG Life Sciences Limited |
RPGLIFE |
INE105J01010 |
Dividend - Rs 9.60 Per Share |
14 Jul 2022 |
8 |
N/A |
RPG Life Sciences Limited |
RPGLIFE |
INE105J01010 |
Dividend - Rs 7.20 Per Share |
13 Aug 2021 |
8 |
N/A |
RPG Life Sciences Limited |
RPGLIFE |
INE105J01010 |
Interim Dividend - Rs 4 Per Share |
24 Mar 2020 |
8 |
N/A |
NSE: RPGLIFE Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
RPGLIFE |
03 Jan 2025, 17:46:22 |
General Updates |
Pharmaceuticals |
RPGLIFE |
01 Jan 2025, 19:55:57 |
Updates |
Pharmaceuticals |
RPGLIFE |
30 Dec 2024, 12:58:05 |
Trading Window-XBRL |
Pharmaceuticals |
RPGLIFE |
27 Dec 2024, 16:46:05 |
Loss/Duplicate-Share Certificate-XBRL |
Pharmaceuticals |
RPGLIFE |
27 Dec 2024, 16:41:47 |
Loss of Share Certificates |
Pharmaceuticals |
NSE: RPGLIFE Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
RPG Life Sciences Limited |
RPGLIFE |
21 Oct 2024, 18:54:00 |
21 Oct 2024, 18:54:00 |
|
RPG Life Sciences Limited |
RPGLIFE |
19 Jul 2024, 15:37:00 |
19 Jul 2024, 15:37:00 |
|
RPG Life Sciences Limited |
RPGLIFE |
19 Apr 2024, 20:04:00 |
19 Apr 2024, 20:30:00 |
|
RPG Life Sciences Limited |
RPGLIFE |
17 Jan 2024, 16:00:00 |
17 Jan 2024, 16:30:00 |
|
RPG Life Sciences Limited |
RPGLIFE |
16 Oct 2023, 20:00:00 |
16 Oct 2023, 20:30:00 |
NSE: RPGLIFE Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson Related To Promoters,Non-Executive Director |
10 Dec 1957 |
06 Feb 2008 |
00026726 |
Harsh V. Goenka |
Active |
Independent Director |
30 Mar 1941 |
25 Sep 2014 |
00008050 |
Lalit S. Kanodia |
Active |
Independent Director |
30 Jun 1956 |
25 Sep 2014 |
00046810 |
Mahesh S. Gupta |
Active |
Independent Director |
08 Aug 1957 |
25 Sep 2014 |
00012341 |
Manoj Maheshwari |
Active |
Independent Director |
15 Nov 1948 |
25 Sep 2014 |
00236658 |
Narendra Ambwani |
Active |
NSE: RPGLIFE Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
RPGLIFE |
N/A |
INE105J01010 |
RPG Life Sciences Limited |
31 Oct 2024, 17:42:52 |
Financial Results |
RPGLIFE |
N/A |
INE105J01010 |
RPG Life Sciences Limited |
12 Jul 2024, 19:12:19 |
RPG LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 30-Apr-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend. |
RPGLIFE |
N/A |
INE105J01010 |
RPG Life Sciences Limited |
23 Apr 2024, 18:44:02 |
Financial Results |
RPGLIFE |
N/A |
INE105J01010 |
RPG Life Sciences Limited |
25 Jan 2024, 18:26:02 |
Financial Results |
RPGLIFE |
N/A |
INE105J01010 |
RPG Life Sciences Limited |
11 Oct 2023, 17:59:02 |
NSE: RPGLIFE Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
RPGLIFE |
- |
INE105J01010 |
RPG Life Sciences Limited |
31 Oct 2024, 00:00:00 |
To consider and approve the unaudited financial results for the period ended September 30, 2024 |
Financial Results |
RPGLIFE |
- |
INE105J01010 |
RPG Life Sciences Limited |
12 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results/Dividend |
RPGLIFE |
- |
INE105J01010 |
RPG Life Sciences Limited |
23 Apr 2024, 00:00:00 |
the Audited Financial Results for the quarter and year ended March 31, 2024 and to consider and recommend dividend on equity shares , if any, for the year ended March 31, 2024 |
Financial Results |
RPGLIFE |
- |
INE105J01010 |
RPG Life Sciences Limited |
25 Jan 2024, 00:00:00 |
To consider and approve the financial results for the quarter and nine months ended December 31, 2023 |
Financial Results |
RPGLIFE |
- |
INE105J01010 |
RPG Life Sciences Limited |
11 Oct 2023, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2023 |
NSE: RPGLIFE Balance Sheet Data In (Cr)
| date | period_type | Treasury Shares Number | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Non Current Pension And Other Postretirement Benefit Plans | Non Current Deferred Revenue | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Defined Pension Benefit | Non Current Prepaid Assets | Non Current Deferred Taxes Assets | Financial Assets | Investmentin Financial Assets | Available For Sale Securities | Goodwill And Other Intangible Assets | Other Intangible Assets | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Hedging Assets Current | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 0.00 | 16,539,015.00 | 16,539,015.00 | 0.00 | 0.00 | 3,536,700,000.00 | 3,793,800,000.00 | 1,622,400,000.00 | 3,536,700,000.00 | 0.00 | 3,793,800,000.00 | 3,793,800,000.00 | 3,793,800,000.00 | 3,793,800,000.00 | 3,661,500,000.00 | 0.00 | 0.00 | 132,300,000.00 | 132,300,000.00 | 1,749,900,000.00 | 70,600,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 41,500,000.00 | 1,679,300,000.00 | 580,800,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 135,500,000.00 | 752,700,000.00 | 0.00 | 0.00 | 60,700,000.00 | 692,000,000.00 | 5,543,700,000.00 | 2,242,000,000.00 | 11,400,000.00 | 0.00 | 0.00 | 7,200,000.00 | 0.00 | 14,400,000.00 | 14,400,000.00 | 257,100,000.00 | 257,100,000.00 | 1,817,900,000.00 | 0.00 | 1,817,900,000.00 | 143,200,000.00 | 1,674,700,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,301,700,000.00 | 168,700,000.00 | 0.00 | 0.00 | 0.00 | 991,600,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 864,100,000.00 | 0.00 | 0.00 | 1,277,300,000.00 | 1,104,500,000.00 | 172,800,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 0.00 | 16,539,015.00 | 16,539,015.00 | 0.00 | 0.00 | 3,468,200,000.00 | 3,748,500,000.00 | 1,671,300,000.00 | 3,468,200,000.00 | 0.00 | 3,748,500,000.00 | 3,748,500,000.00 | 3,748,500,000.00 | 3,748,500,000.00 | 3,616,200,000.00 | 3,184,800,000.00 | 344,600,000.00 | 132,300,000.00 | 132,300,000.00 | 1,380,200,000.00 | 70,600,000.00 | 40,300,000.00 | 30,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40,300,000.00 | 1,309,600,000.00 | 52,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 121,700,000.00 | 1,169,500,000.00 | 425,800,000.00 | 6,300,000.00 | 27,200,000.00 | 710,200,000.00 | 5,128,700,000.00 | 2,147,800,000.00 | 15,100,000.00 | 0.00 | 19,400,000.00 | 5,800,000.00 | 0.00 | 10,100,000.00 | 10,100,000.00 | 280,300,000.00 | 280,300,000.00 | 1,818,100,000.00 | -574,600,000.00 | 2,392,700,000.00 | 847,800,000.00 | 970,300,000.00 | 865,900,000.00 | 477,000,000.00 | 202,000,000.00 | 0.00 | 2,980,900,000.00 | 203,100,000.00 | 0.00 | 7,500,000.00 | 195,300,000.00 | 1,010,000,000.00 | 56,300,000.00 | 564,400,000.00 | 148,900,000.00 | 240,400,000.00 | 18,100,000.00 | 491,300,000.00 | -40,300,000.00 | 531,600,000.00 | 1,258,700,000.00 | 1,061,500,000.00 | 197,200,000.00 | 170,000,000.00 | 27,200,000.00 |
| 2024-03-31T00:00:00 | annual | 0.00 | 16,539,015.00 | 16,539,015.00 | 0.00 | 0.00 | 3,468,200,000.00 | 3,748,500,000.00 | 1,671,300,000.00 | 3,468,200,000.00 | 0.00 | 3,748,500,000.00 | 3,748,500,000.00 | 3,748,500,000.00 | 3,748,500,000.00 | 3,616,200,000.00 | 3,184,800,000.00 | 344,600,000.00 | 132,300,000.00 | 132,300,000.00 | 1,380,200,000.00 | 70,600,000.00 | 40,300,000.00 | 30,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40,300,000.00 | 1,309,600,000.00 | 52,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 121,700,000.00 | 1,169,500,000.00 | 425,800,000.00 | 6,300,000.00 | 27,200,000.00 | 710,200,000.00 | 5,128,700,000.00 | 2,147,800,000.00 | 15,100,000.00 | 0.00 | 19,400,000.00 | 5,800,000.00 | 0.00 | 10,100,000.00 | 10,100,000.00 | 280,300,000.00 | 280,300,000.00 | 1,818,100,000.00 | -574,600,000.00 | 2,392,700,000.00 | 847,800,000.00 | 970,300,000.00 | 865,900,000.00 | 477,000,000.00 | 202,000,000.00 | 0.00 | 2,980,900,000.00 | 203,100,000.00 | 0.00 | 7,500,000.00 | 195,300,000.00 | 1,010,000,000.00 | 56,300,000.00 | 564,400,000.00 | 148,900,000.00 | 240,400,000.00 | 18,100,000.00 | 491,300,000.00 | -40,300,000.00 | 531,600,000.00 | 1,258,700,000.00 | 1,061,500,000.00 | 197,200,000.00 | 170,000,000.00 | 27,200,000.00 |
| 2023-09-30T00:00:00 | quarterly | 0.00 | 16,539,015.00 | 16,539,015.00 | 0.00 | 0.00 | 3,056,200,000.00 | 3,357,400,000.00 | 1,630,200,000.00 | 3,056,200,000.00 | 0.00 | 3,357,400,000.00 | 3,357,400,000.00 | 3,357,400,000.00 | 3,357,400,000.00 | 3,225,100,000.00 | 0.00 | 0.00 | 132,300,000.00 | 132,300,000.00 | 1,254,000,000.00 | 80,500,000.00 | 0.00 | 0.00 | 9,600,000.00 | 0.00 | 0.00 | 0.00 | 40,600,000.00 | 1,173,500,000.00 | 51,600,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116,100,000.00 | 750,100,000.00 | 0.00 | 0.00 | 60,100,000.00 | 690,000,000.00 | 4,611,400,000.00 | 1,807,700,000.00 | 83,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,400,000.00 | 4,400,000.00 | 301,200,000.00 | 301,200,000.00 | 1,397,700,000.00 | 0.00 | 1,397,700,000.00 | 419,100,000.00 | 978,600,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,803,700,000.00 | 166,300,000.00 | 0.00 | 0.00 | 0.00 | 1,005,700,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200,000.00 | 600,700,000.00 | 0.00 | 0.00 | 1,030,800,000.00 | 807,600,000.00 | 223,200,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 0.00 | 16,539,015.00 | 16,539,015.00 | 0.00 | 100,000.00 | 2,742,000,000.00 | 3,076,100,000.00 | 1,612,700,000.00 | 2,742,000,000.00 | 0.00 | 3,076,000,000.00 | 3,076,000,000.00 | 3,076,000,000.00 | 3,076,000,000.00 | 0.00 | 2,512,300,000.00 | 344,600,000.00 | 132,300,000.00 | 132,300,000.00 | 1,117,500,000.00 | 89,700,000.00 | 39,800,000.00 | 30,200,000.00 | 19,700,000.00 | 0.00 | 0.00 | 0.00 | 39,800,000.00 | 1,027,800,000.00 | 62,000,000.00 | 100,000.00 | 0.00 | 100,000.00 | 0.00 | 118,600,000.00 | 891,200,000.00 | 238,800,000.00 | 5,500,000.00 | 0.00 | 646,900,000.00 | 4,193,500,000.00 | 1,553,000,000.00 | 32,500,000.00 | 0.00 | 36,900,000.00 | 0.00 | 0.00 | 0.00 | 4,400,000.00 | 334,000,000.00 | 334,000,000.00 | 1,163,000,000.00 | -518,800,000.00 | 1,681,800,000.00 | 150,300,000.00 | 1,012,700,000.00 | 865,400,000.00 | 464,100,000.00 | 202,000,000.00 | 0.00 | 2,640,500,000.00 | 147,300,000.00 | 200,000.00 | 6,700,000.00 | 146,200,000.00 | 950,500,000.00 | 35,500,000.00 | 563,100,000.00 | 177,200,000.00 | 174,700,000.00 | 14,600,000.00 | 374,300,000.00 | -13,300,000.00 | 387,600,000.00 | 1,148,000,000.00 | 899,800,000.00 | 248,200,000.00 | 224,500,000.00 | 23,700,000.00 |
| 2023-03-31T00:00:00 | annual | 0.00 | 16,539,015.00 | 16,539,015.00 | 0.00 | 100,000.00 | 2,742,000,000.00 | 3,076,100,000.00 | 1,612,700,000.00 | 2,742,000,000.00 | 0.00 | 3,076,000,000.00 | 3,076,000,000.00 | 3,076,000,000.00 | 3,076,000,000.00 | 0.00 | 2,512,300,000.00 | 344,600,000.00 | 132,300,000.00 | 132,300,000.00 | 1,117,500,000.00 | 89,700,000.00 | 39,800,000.00 | 30,200,000.00 | 19,700,000.00 | 0.00 | 0.00 | 0.00 | 39,800,000.00 | 1,027,800,000.00 | 62,000,000.00 | 100,000.00 | 0.00 | 100,000.00 | 0.00 | 118,600,000.00 | 891,200,000.00 | 238,800,000.00 | 5,500,000.00 | 0.00 | 646,900,000.00 | 4,193,500,000.00 | 1,553,000,000.00 | 32,500,000.00 | 0.00 | 36,900,000.00 | 0.00 | 0.00 | 0.00 | 4,400,000.00 | 334,000,000.00 | 334,000,000.00 | 1,163,000,000.00 | -518,800,000.00 | 1,681,800,000.00 | 150,300,000.00 | 1,012,700,000.00 | 865,400,000.00 | 464,100,000.00 | 202,000,000.00 | 0.00 | 2,640,500,000.00 | 147,300,000.00 | 200,000.00 | 6,700,000.00 | 146,200,000.00 | 950,500,000.00 | 35,500,000.00 | 563,100,000.00 | 177,200,000.00 | 174,700,000.00 | 14,600,000.00 | 374,300,000.00 | -13,300,000.00 | 387,600,000.00 | 1,148,000,000.00 | 899,800,000.00 | 248,200,000.00 | 224,500,000.00 | 23,700,000.00 |
| 2022-03-31T00:00:00 | annual | 0.00 | 16,539,015.00 | 16,539,015.00 | 0.00 | 9,400,000.00 | 2,210,900,000.00 | 2,560,600,000.00 | 1,268,000,000.00 | 2,210,900,000.00 | 6,500,000.00 | 2,557,700,000.00 | 2,557,800,000.00 | 2,557,700,000.00 | 2,557,700,000.00 | 0.00 | 1,994,000,000.00 | 344,600,000.00 | 132,300,000.00 | 132,300,000.00 | 888,400,000.00 | 87,300,000.00 | 30,400,000.00 | 31,300,000.00 | 22,600,000.00 | 3,000,000.00 | 2,900,000.00 | 100,000.00 | 30,400,000.00 | 801,100,000.00 | 55,600,000.00 | 6,400,000.00 | 3,600,000.00 | 2,800,000.00 | 0.00 | 141,500,000.00 | 628,600,000.00 | 165,400,000.00 | 4,400,000.00 | 3,800,000.00 | 455,000,000.00 | 3,446,100,000.00 | 1,377,000,000.00 | 11,800,000.00 | 0.00 | 15,600,000.00 | 0.00 | 0.00 | 3,800,000.00 | 3,800,000.00 | 346,800,000.00 | 346,800,000.00 | 1,000,900,000.00 | -455,800,000.00 | 1,456,700,000.00 | 254,500,000.00 | 746,400,000.00 | 670,500,000.00 | 329,700,000.00 | 202,000,000.00 | 0.00 | 2,069,100,000.00 | 191,600,000.00 | 0.00 | 4,600,000.00 | 163,900,000.00 | 829,900,000.00 | 28,500,000.00 | 496,000,000.00 | 171,300,000.00 | 134,100,000.00 | 42,800,000.00 | 329,900,000.00 | -10,000,000.00 | 339,900,000.00 | 698,000,000.00 | 128,600,000.00 | 569,400,000.00 | 561,400,000.00 | 8,000,000.00 |
| 2021-03-31T00:00:00 | annual | 0.00 | 16,539,015.00 | 16,539,015.00 | 0.00 | 20,200,000.00 | 1,793,200,000.00 | 2,171,700,000.00 | 961,600,000.00 | 1,793,200,000.00 | 13,000,000.00 | 2,164,500,000.00 | 2,165,400,000.00 | 2,164,500,000.00 | 2,164,500,000.00 | 0.00 | 1,600,800,000.00 | 344,600,000.00 | 132,300,000.00 | 132,300,000.00 | 869,400,000.00 | 72,500,000.00 | 31,300,000.00 | 33,800,000.00 | 0.00 | 7,400,000.00 | 6,500,000.00 | 900,000.00 | 31,300,000.00 | 796,900,000.00 | 64,400,000.00 | 12,800,000.00 | 6,500,000.00 | 6,300,000.00 | 98,400,000.00 | 136,100,000.00 | 609,100,000.00 | 130,800,000.00 | 3,900,000.00 | 0.00 | 474,400,000.00 | 3,033,900,000.00 | 1,275,400,000.00 | 7,200,000.00 | 0.00 | 10,000,000.00 | 600,000.00 | 0.00 | 2,800,000.00 | 2,800,000.00 | 371,300,000.00 | 371,300,000.00 | 879,400,000.00 | -368,900,000.00 | 1,248,300,000.00 | 94,400,000.00 | 785,000,000.00 | 628,300,000.00 | 323,600,000.00 | 202,000,000.00 | 0.00 | 1,758,500,000.00 | 182,100,000.00 | 0.00 | 3,900,000.00 | 149,200,000.00 | 583,300,000.00 | 23,500,000.00 | 312,400,000.00 | 102,800,000.00 | 144,600,000.00 | 44,300,000.00 | 574,200,000.00 | -10,000,000.00 | 584,200,000.00 | 403,600,000.00 | 15,300,000.00 | 403,600,000.00 | 391,800,000.00 | 11,800,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 92,400,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19,400,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15,200,000.00 | 13,000,000.00 | 2,200,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6,400,000.00 | 0.00 | 88,600,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: RPGLIFE Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Short Term Debt Payments | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Capital Expenditure Reported | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 251,300,000.00 | 0.00 | 0.00 | -692,300,000.00 | 197,200,000.00 | 0.00 | 248,200,000.00 | -51,000,000.00 | -203,100,000.00 | 0.00 | -4,500,000.00 | -198,500,000.00 | -198,500,000.00 | -100,000.00 | 0.00 | 0.00 | -100,000.00 | 0.00 | 0.00 | -791,500,000.00 | 154,700,000.00 | 14,200,000.00 | -114,900,000.00 | 330,200,000.00 | -445,100,000.00 | -690,800,000.00 | 1,500,000.00 | -692,300,000.00 | 0.00 | 943,600,000.00 | -293,100,000.00 | -70,900,000.00 | 124,100,000.00 | -52,600,000.00 | 63,300,000.00 | -59,500,000.00 | -142,300,000.00 | -9,700,000.00 | 27,000,000.00 | 170,700,000.00 | 66,600,000.00 | 104,100,000.00 | -57,700,000.00 | -1,000,000.00 | -100,000.00 | 1,178,400,000.00 |
| 2023-03-31T00:00:00 | annual | 580,900,000.00 | -2,700,000.00 | 0.00 | -327,300,000.00 | 248,200,000.00 | -100,000.00 | 569,400,000.00 | -321,100,000.00 | -171,200,000.00 | -100,000.00 | -3,100,000.00 | -158,800,000.00 | -158,800,000.00 | -2,800,000.00 | -2,700,000.00 | -2,700,000.00 | -100,000.00 | 0.00 | 0.00 | -1,058,100,000.00 | -189,000,000.00 | 27,300,000.00 | -758,900,000.00 | 0.00 | -758,900,000.00 | -326,500,000.00 | 800,000.00 | -327,300,000.00 | 0.00 | 908,200,000.00 | -252,300,000.00 | 110,500,000.00 | 60,200,000.00 | 45,700,000.00 | 192,600,000.00 | -120,600,000.00 | -54,800,000.00 | -24,200,000.00 | 4,300,000.00 | 155,000,000.00 | 67,900,000.00 | 87,100,000.00 | -14,400,000.00 | 4,600,000.00 | 7,800,000.00 | 916,800,000.00 |
| 2022-03-31T00:00:00 | annual | 408,000,000.00 | -4,200,000.00 | 0.00 | -239,500,000.00 | 569,400,000.00 | 0.00 | 403,600,000.00 | 165,800,000.00 | -135,100,000.00 | 0.00 | -5,200,000.00 | -119,100,000.00 | -119,100,000.00 | -4,200,000.00 | -3,100,000.00 | -3,100,000.00 | -1,100,000.00 | -1,100,000.00 | 0.00 | -346,600,000.00 | -700,000.00 | 13,300,000.00 | -119,700,000.00 | 8,900,000.00 | -128,600,000.00 | -239,500,000.00 | 0.00 | -239,500,000.00 | 0.00 | 647,500,000.00 | -188,500,000.00 | -31,100,000.00 | -4,400,000.00 | -9,000,000.00 | -19,100,000.00 | -246,600,000.00 | 247,100,000.00 | -8,100,000.00 | 500,000.00 | 156,600,000.00 | 68,300,000.00 | 88,300,000.00 | -8,900,000.00 | -4,700,000.00 | 0.00 | 731,700,000.00 |
| 2021-03-31T00:00:00 | annual | 497,600,000.00 | -90,700,000.00 | 0.00 | -85,100,000.00 | 403,600,000.00 | 0.00 | 5,400,000.00 | 398,200,000.00 | -104,900,000.00 | 0.00 | -7,900,000.00 | 0.00 | 0.00 | -90,700,000.00 | -46,000,000.00 | -46,000,000.00 | -44,700,000.00 | -44,700,000.00 | 0.00 | -79,600,000.00 | 1,800,000.00 | 3,200,000.00 | 0.00 | 0.00 | 0.00 | -84,600,000.00 | 500,000.00 | -85,100,000.00 | -85,100,000.00 | 582,700,000.00 | -83,300,000.00 | -35,300,000.00 | 23,100,000.00 | -45,600,000.00 | 31,200,000.00 | -117,200,000.00 | 62,200,000.00 | 4,700,000.00 | -100,000.00 | 164,700,000.00 | 69,800,000.00 | 94,900,000.00 | 0.00 | -3,900,000.00 | 100,000.00 | 535,800,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | -2,100,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -127,700,000.00 | 0.00 | 0.00 | 0.00 | -239,200,000.00 | 0.00 | -2,100,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -107,400,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: RPGLIFE Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Impairment Of Capital Assets | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 1.48 | 0.00 | 129.58 | 5.78 | 5.78 | 87.66 | 17.07 | 194.20 | 135.36 | 118.29 | -0.02 | 0.45 | 1.42 | 83.36 | 87.66 | 465.41 | 0.74 | 1.65 | 1.65 | 0.00 | 0.00 | 87.66 | 87.66 | 0.00 | 87.66 | 87.66 | 87.66 | 30.18 | 117.84 | 7.21 | 0.01 | -0.01 | 0.00 | 0.00 | -0.02 | 0.99 | 0.45 | 1.42 | 112.07 | 271.21 | 63.72 | 17.07 | 6.66 | 10.41 | 60.90 | 37.85 | 23.05 | 0.74 | 383.28 | 194.20 | 577.48 | 577.48 |
| 2023-03-31T00:00:00 | annual | 0.17 | 0.00 | 106.83 | 0.66 | 0.66 | 67.64 | 15.50 | 178.23 | 107.49 | 91.99 | 1.58 | 0.31 | 2.73 | 67.15 | 67.64 | 420.20 | 0.69 | 1.65 | 1.65 | 0.00 | 0.00 | 67.64 | 67.64 | 0.00 | 67.64 | 67.64 | 67.64 | 24.04 | 91.68 | 0.06 | -0.78 | 0.78 | 0.00 | 0.00 | 1.58 | 0.84 | 0.31 | 2.73 | 88.88 | 241.97 | 55.21 | 15.50 | 6.79 | 8.71 | 55.88 | 35.62 | 20.26 | 0.69 | 330.85 | 178.23 | 509.08 | 509.08 |
| 2022-03-31T00:00:00 | annual | 0.24 | 0.00 | 88.55 | 0.80 | 0.80 | 51.48 | 15.66 | 150.21 | 89.35 | 73.69 | -0.08 | 0.52 | 1.33 | 50.92 | 51.48 | 365.44 | 0.66 | 1.65 | 1.65 | 0.00 | 0.00 | 51.48 | 51.48 | 0.00 | 51.48 | 51.48 | 51.48 | 21.69 | 73.17 | 2.99 | -0.09 | 0.00 | 0.09 | 0.00 | -0.08 | 0.89 | 0.52 | 1.33 | 71.72 | 215.23 | 47.42 | 15.66 | 6.83 | 8.83 | 53.56 | 32.27 | 21.29 | 0.66 | 286.95 | 150.21 | 437.16 | 437.16 |
| 2021-03-31T00:00:00 | annual | -0.04 | 0.00 | 71.01 | -0.17 | -0.17 | 40.00 | 16.47 | 137.64 | 70.84 | 54.37 | -1.47 | 0.79 | 0.32 | 40.13 | 40.00 | 328.67 | 0.70 | 1.65 | 1.65 | 0.00 | 0.00 | 40.00 | 40.00 | 0.00 | 40.00 | 40.00 | 40.00 | 13.58 | 53.58 | 0.10 | -0.17 | 0.01 | 0.16 | 0.00 | -1.47 | 1.00 | 0.79 | 0.32 | 54.72 | 191.03 | 41.72 | 16.47 | 6.98 | 9.49 | 42.15 | 25.47 | 16.68 | 0.70 | 245.75 | 137.64 | 383.39 | 383.39 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.26 | 5.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
6/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
42.65
P/E
51.0762
P/B
9.494628
Dividend Yield
0.72%
Market Cap
3,602.86 Cr.
Face Value
229.435
Book Value
229.435
ROE
11.43%
EBITDA Growth
142.61 Cr.
Debt/Equity
N/A
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of rpglife?
The market capitalization of RPG Life Sciences Limited is ₹3,603 Cr as of 05 Feb 2025.
What are the PE and PB ratios of RPG Life Sciences Limited?
The PE and PB ratios of RPG Life Sciences Limited are Not Available and 9.494628 respectively as of 05 Feb 2025.
What is the 52 Week High of RPG Life Sciences Limited?
The 52-week high of RPG Life Sciences Limited is ₹2974.95 as of 05 Feb 2025.
What is the 52 Week Low of RPG Life Sciences Limited?
The 52-week low of RPG Life Sciences Limited is ₹1307 as of 05 Feb 2025.
What are the earnings per share (EPS) for RPG Life Sciences Limited?
The Earnings Per Share (EPS) of RPG Life Sciences Limited is ₹42.65 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of RPG Life Sciences Limited?
The Return on Equity (ROE) of RPG Life Sciences Limited is 11.43% as per the most recent financial year data. Explore more on Fincept.